Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Billing Codes · Pharmacy · Oncology, Hematology, Pediatrics +1 moreMedium impact

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Act
by Dec 15, 2025
Effective date
Jan 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued Medicare Advantage policy MA08.085k on the Rylaze® drug with no substantive changes to coverage criteria. However, the deprecated HCPCS code J9019 (asparaginase Erwinaze) has been removed and replaced with J9021 (asparaginase recombinant Rylaze). Billing teams must update systems to use only J9021 for claims effective January 1, 2026.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Dec 15, 2025 · 5 steps
01Billing team must update billing software and claims submission systems to discontinue use of HCPCS code J9019 (asparaginase Erwinaze) and transition all Rylaze® claims to HCPCS code J9021 (asparaginase recombinant Rylaze).
02Update charge masters, templates, and provider encounter forms to reflect the new code.
03Educate oncology and hematology providers that J9019 is no longer valid as of January 1, 2026.
04Beginning January 1, 2026, any claims submitted with J9019 will be denied by Independence Blue Cross Medicare Advantage plans.
05Verify that all outstanding claims using J9019 are resubmitted with J9021 before the effective date.

Codes mentioned

J9019J9021

Original notice

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)LowEffective Jan 1, 2026 · Pharmacy08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · Pharmacy08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · PharmacyMA08.085i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyHematologyPediatricsPharmacyCode J9019Code J9021

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account